MA69210B1 - Composition à libération prolongée solide comprenant des antagonistes du récepteur b2 de la bradykinine - Google Patents
Composition à libération prolongée solide comprenant des antagonistes du récepteur b2 de la bradykinineInfo
- Publication number
- MA69210B1 MA69210B1 MA69210A MA69210A MA69210B1 MA 69210 B1 MA69210 B1 MA 69210B1 MA 69210 A MA69210 A MA 69210A MA 69210 A MA69210 A MA 69210A MA 69210 B1 MA69210 B1 MA 69210B1
- Authority
- MA
- Morocco
- Prior art keywords
- bradykinin
- matrix
- methyl
- receptor antagonists
- release composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22164471 | 2022-03-25 | ||
| EP23715488.5A EP4499039B1 (en) | 2022-03-25 | 2023-03-27 | Solid extended-release composition comprising bradykinin b2-receptor antagonists |
| PCT/EP2023/057792 WO2023180576A1 (en) | 2022-03-25 | 2023-03-27 | Solid extended-release composition comprising bradykinin b2-receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA69210B1 true MA69210B1 (fr) | 2026-02-27 |
Family
ID=80952430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA69210A MA69210B1 (fr) | 2022-03-25 | 2023-03-27 | Composition à libération prolongée solide comprenant des antagonistes du récepteur b2 de la bradykinine |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20250228782A1 (enExample) |
| EP (2) | EP4499039B1 (enExample) |
| JP (1) | JP2025510860A (enExample) |
| KR (1) | KR20240161195A (enExample) |
| CN (1) | CN119136786A (enExample) |
| AU (1) | AU2023240388A1 (enExample) |
| CA (1) | CA3250834A1 (enExample) |
| CO (1) | CO2024012885A2 (enExample) |
| DK (1) | DK4499039T3 (enExample) |
| ES (1) | ES3062435T3 (enExample) |
| FI (1) | FI4499039T3 (enExample) |
| HR (1) | HRP20260203T1 (enExample) |
| IL (1) | IL315700A (enExample) |
| LT (1) | LT4499039T (enExample) |
| MA (1) | MA69210B1 (enExample) |
| MX (1) | MX2024011704A (enExample) |
| PL (1) | PL4499039T3 (enExample) |
| PT (1) | PT4499039T (enExample) |
| RS (1) | RS67776B1 (enExample) |
| SI (1) | SI4499039T1 (enExample) |
| SM (1) | SMT202600057T1 (enExample) |
| TW (1) | TW202345810A (enExample) |
| WO (1) | WO2023180576A1 (enExample) |
| ZA (1) | ZA202408059B (enExample) |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1168667A (zh) | 1994-10-27 | 1997-12-24 | 藤沢药品工业株式会社 | 用作缓激肽拮抗剂的吡啶并嘧啶酮，喹啉和稠合的n-杂环化合物 |
| FR2737892B1 (fr) | 1995-08-17 | 1997-10-24 | Fournier Ind & Sante | Nouveaux composes de benzenesulfonamide, procede de preparation et utilisation en therapeutique |
| GB9602029D0 (en) | 1996-02-01 | 1996-04-03 | Fujisawa Pharmaceutical Co | New heterocyclic compounds |
| DE19609827A1 (de) | 1996-03-13 | 1997-09-18 | Hoechst Ag | Aminoalkyl- und Acylaminoalkylether, Verfahren zu deren Herstellung und ihre Verwendung als Bradykinin-Rezeptorantagonisten |
| DE19610784A1 (de) | 1996-03-19 | 1997-09-25 | Hoechst Ag | Fluoralkyl- und Fluoralkoxysubstituierte heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung |
| AUPN952696A0 (en) | 1996-04-29 | 1996-05-23 | Fujisawa Pharmaceutical Co., Ltd. | New heterocyclic compounds |
| DE19712960A1 (de) | 1997-03-27 | 1998-10-01 | Hoechst Ag | Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten |
| EP1085895A1 (en) | 1998-06-08 | 2001-03-28 | Advanced Medicine, Inc. | Bradykinin antagonists |
| EP1123288A1 (en) | 1998-10-21 | 2001-08-16 | Fujisawa Pharmaceutical Co., Ltd. | Vitreous form of known bradykinin antagonist |
| FR2790260B1 (fr) | 1999-02-26 | 2001-05-04 | Fournier Ind & Sante | Nouveaux composes de n-(benzenesulfonamide), procede de preparation et utilisation en therapeutique |
| CA2364178C (en) | 2000-12-05 | 2006-01-10 | Yasuhiro Katsu | N-benzenesulfonyl l-proline compounds as bradykinin antagonists |
| JP2005525398A (ja) | 2002-04-10 | 2005-08-25 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | ブラジキニン受容体モジュレーターとして有用な新規なヘテロアリールアルキルアミド誘導体 |
| ITMI20021247A1 (it) | 2002-06-07 | 2003-12-09 | Menarini Ricerche Spa | Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche |
| ITMI20041963A1 (it) | 2004-10-15 | 2005-01-15 | Luso Farmaco Inst | "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche" |
| TWI407960B (zh) | 2007-03-23 | 2013-09-11 | Jerini Ag | 小分子緩激肽ｂ２受體調節劑 |
| AR073304A1 (es) | 2008-09-22 | 2010-10-28 | Jerini Ag | Moduladores del receptor de bradiquinina b2 de molecula pequena |
| KR20150127718A (ko) | 2013-03-14 | 2015-11-17 | 샤이어 휴먼 지네틱 테라피즈 인크. | Ｂ2-브라디키닌 수용체 매개 혈관부종의 치료 방법 |
| SMT202200154T1 (it) * | 2017-11-24 | 2022-05-12 | Pharvaris Netherlands B V | Nuovi antagonisti del recettore della bradichinina b2 |
| AR118983A1 (es) * | 2019-05-23 | 2021-11-17 | Pharvaris Gmbh | Antagonistas cíclicos del receptor b2 de bradiquinina |
| CA3198246A1 (en) * | 2020-11-12 | 2022-05-19 | Pharvaris Gmbh | Prophylaxis and treatment of angioedema |
-
2023
- 2023-03-25 TW TW112111337A patent/TW202345810A/zh unknown
- 2023-03-27 PL PL23715488.5T patent/PL4499039T3/pl unknown
- 2023-03-27 EP EP23715488.5A patent/EP4499039B1/en active Active
- 2023-03-27 CN CN202380037796.5A patent/CN119136786A/zh active Pending
- 2023-03-27 AU AU2023240388A patent/AU2023240388A1/en active Pending
- 2023-03-27 SM SM20260057T patent/SMT202600057T1/it unknown
- 2023-03-27 WO PCT/EP2023/057792 patent/WO2023180576A1/en not_active Ceased
- 2023-03-27 ES ES23715488T patent/ES3062435T3/es active Active
- 2023-03-27 MA MA69210A patent/MA69210B1/fr unknown
- 2023-03-27 RS RS20260209A patent/RS67776B1/sr unknown
- 2023-03-27 US US18/850,683 patent/US20250228782A1/en active Pending
- 2023-03-27 EP EP25219557.3A patent/EP4684830A3/en active Pending
- 2023-03-27 SI SI202330074T patent/SI4499039T1/sl unknown
- 2023-03-27 HR HRP20260203TT patent/HRP20260203T1/hr unknown
- 2023-03-27 JP JP2024556788A patent/JP2025510860A/ja active Pending
- 2023-03-27 DK DK23715488.5T patent/DK4499039T3/da active
- 2023-03-27 LT LTEPPCT/EP2023/057792T patent/LT4499039T/lt unknown
- 2023-03-27 FI FIEP23715488.5T patent/FI4499039T3/fi active
- 2023-03-27 KR KR1020247035307A patent/KR20240161195A/ko active Pending
- 2023-03-27 IL IL315700A patent/IL315700A/en unknown
- 2023-03-27 CA CA3250834A patent/CA3250834A1/en active Pending
- 2023-03-27 PT PT237154885T patent/PT4499039T/pt unknown
-
2024
- 2024-09-24 MX MX2024011704A patent/MX2024011704A/es unknown
- 2024-09-24 CO CONC2024/0012885A patent/CO2024012885A2/es unknown
- 2024-10-24 ZA ZA2024/08059A patent/ZA202408059B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20250228782A1 (en) | 2025-07-17 |
| SI4499039T1 (sl) | 2026-04-30 |
| IL315700A (en) | 2024-11-01 |
| LT4499039T (lt) | 2026-02-25 |
| ES3062435T3 (en) | 2026-04-10 |
| AU2023240388A1 (en) | 2024-11-07 |
| PT4499039T (pt) | 2026-02-17 |
| CO2024012885A2 (es) | 2024-10-10 |
| PL4499039T3 (pl) | 2026-03-30 |
| TW202345810A (zh) | 2023-12-01 |
| FI4499039T3 (fi) | 2026-02-05 |
| MX2024011704A (es) | 2024-11-08 |
| JP2025510860A (ja) | 2025-04-15 |
| EP4499039B1 (en) | 2025-12-03 |
| CN119136786A (zh) | 2024-12-13 |
| ZA202408059B (en) | 2026-01-28 |
| SMT202600057T1 (it) | 2026-03-09 |
| HRP20260203T1 (hr) | 2026-03-27 |
| EP4499039A1 (en) | 2025-02-05 |
| DK4499039T3 (da) | 2026-02-16 |
| EP4684830A2 (en) | 2026-01-28 |
| CA3250834A1 (en) | 2023-09-28 |
| KR20240161195A (ko) | 2024-11-12 |
| WO2023180576A1 (en) | 2023-09-28 |
| EP4684830A3 (en) | 2026-04-01 |
| RS67776B1 (sr) | 2026-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11267801B2 (en) | Therapeutic compounds | |
| JP6356919B2 (ja) | Ｈｉｖの処置のためのイソキノリン化合物 | |
| CN110740993B (zh) | 用作钠通道调节剂的氘代吡啶酮酰胺及其前药 | |
| JP6385584B2 (ja) | Ｈｉｖの処置のための縮合ピリミジン化合物 | |
| JP5561720B2 (ja) | 肥満及び糖尿病を含む心臓血管障害を治療するために有用なカンナビノイド受容体アンタゴニスト／インバ−スアゴニスト | |
| DK1735278T3 (da) | Histamin H3-receptormidler, fremstilling og terapeutiske anvendelser | |
| CN105793245B (zh) | 药物化合物 | |
| CN108602821A (zh) | 1h-咪唑并[4,5-b]吡啶基和2-氧代-2,3-二氢-1h-咪唑并[4,5-b]吡啶基杂环bet溴结构域抑制剂 | |
| TN2013000257A1 (en) | Immunosuppressant formulations | |
| MA33533B1 (fr) | Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles | |
| WO2014110298A1 (en) | 5-membered heteroaryls and their use as antiviral agents | |
| WO2014142607A1 (ko) | 약제학적 복합제제 | |
| KR101354237B1 (ko) | 골수종 치료를 위한 ｈｄａｃ 저해제의 용도 | |
| ZA202408058B (en) | Solid composition comprising solubilised bradykinin b2-receptor antagonists | |
| JP2017537104A (ja) | 変形性関節症におけるσ受容体リガンドの使用 | |
| ZA202408059B (en) | Solid extended-release composition comprising bradykinin b2-receptor antagonists | |
| WO2007009691A2 (en) | Combination of substituted pyrazolines and anti -addictive agent | |
| WO2016189406A1 (en) | Pharmaceutical composition of teriflunomide | |
| EP3697754A1 (en) | Propanamine derivatives for treating pain and pain related conditions | |
| EA053158B1 (ru) | Производные 1,2-замещенного 3-оксопиразолидина в качестве агонистов рецептора 4 простагландина е2 (ep4) для лечения заболеваний желудочно-кишечного тракта и легких | |
| CN119654310A (zh) | 用于治疗胃肠和肺疾病的作为前列腺素e2受体4（ep4）激动剂的1,2-取代的3-氧代吡唑烷衍生物 | |
| KR20090090384A (ko) | 비만 환자에서 고혈압의 예방 및 치료를 위한 레닌 억제제 | |
| HK1246776B (en) | Isoquinoline compounds for the treatment of hiv | |
| TH103210A (th) | ไทรซับสทิทิวเทด 1,2,4-ไทรแอโซล | |
| TH81575A (th) | สารผสมทางเภสัชกรรมสำหรับการบำบัดโรคมะเร็ง |